This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Campion, J. J.
Right arrow Articles by Evans, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campion, J. J.
Right arrow Articles by Evans, M. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4733-4744, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4733-4744.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments

Jeffrey J. Campion,1 Patrick J. McNamara,2 and Martin E. Evans1*

Division of Infectious Diseases, Department of Internal Medicine, College of Medicine,1 Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky2

Received 8 April 2004/ Returned for modification 26 July 2004/ Accepted 19 August 2004

The development of novel antibacterial agents is decreasing despite increasing resistance to presently available agents among common pathogens. Insights into relationships between pharmacodynamics and resistance may provide ways to optimize the use of existing agents. The evolution of resistance was examined in two ciprofloxacin-susceptible Staphylococcus aureus strains exposed to in vitro-simulated clinical and experimental ciprofloxacin pharmacokinetic profiles for 96 h. As the average steady-state concentration (Cavg ss) increased, the rate of killing approached a maximum, and the rate of regrowth decreased. The enrichment of subpopulations with mutations in grlA and low-level ciprofloxacin resistance also varied depending on the pharmacokinetic environment. A regimen producing values for Cavg ss slightly above the MIC selected resistant variants with grlA mutations that did not evolve to higher levels of resistance. Clinical regimens which provided values for Cavg ss intermediate to the MIC and mutant prevention concentration (MPC) resulted in the emergence of subpopulations with gyrA mutations and higher levels of resistance. A regimen producing values for Cavg ss close to the MPC selected grlA mutants, but the appearance of subpopulations with higher levels of resistance was diminished. A regimen designed to maintain ciprofloxacin concentrations entirely above the MPC appeared to eradicate low-level resistant variants in the inoculum and prevent the emergence of higher levels of resistance. There was no relationship between the time that ciprofloxacin concentrations remained between the MIC and the MPC and the degree of resistance or the presence or type of ciprofloxacin-resistance mutations that appeared in grlA or gyrA. Regimens designed to eradicate low-level resistant variants in S. aureus populations may prevent the emergence of higher levels of fluoroquinolone resistance.

* Corresponding author. Mailing address: Division of Infectious Diseases, Department of Internal Medicine, Room MN672, University of Kentucky Medical Center, 800 Rose St., Lexington, KY 40536-0298. Phone: (859) 323-8178. Fax: (859) 323-8926. E-mail: Martin.Evans{at}uky.edu.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4733-4744, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4733-4744.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Allen, G. P., Hankins, C. D. (2009). Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. J Antimicrob Chemother 0: dkp172v1-dkp172 [Abstract] [Full Text]  
  • Firsov, A. A., Lubenko, I. Y., Smirnova, M. V., Strukova, E. N., Zinner, S. H. (2008). Enrichment of Fluoroquinolone-Resistant Staphylococcus aureus: Oscillating Ciprofloxacin Concentrations Simulated at the Upper and Lower Portions of the Mutant Selection Window. Antimicrob. Agents Chemother. 52: 1924-1928 [Abstract] [Full Text]  
  • Oonishi, Y., Mitsuyama, J., Yamaguchi, K. (2007). Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother 60: 1030-1037 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Stromback, A., Hughes, D., Cars, O. (2007). Dose-related selection of fluoroquinolone-resistant Escherichia coli. J Antimicrob Chemother 60: 795-801 [Abstract] [Full Text]  
  • Goessens, W. H. F., Mouton, J. W., ten Kate, M. T., Bijl, A. J., Ott, A., Bakker-Woudenberg, I. A. J. M. (2007). Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 59: 507-516 [Abstract] [Full Text]  
  • Firsov, A. A., Smirnova, M. V., Lubenko, I. Yu., Vostrov, S. N., Portnoy, Y. A., Zinner, S. H. (2006). Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 58: 1185-1192 [Abstract] [Full Text]  
  • Chung, P., McNamara, P. J., Campion, J. J., Evans, M. E. (2006). Mechanism-Based Pharmacodynamic Models of Fluoroquinolone Resistance in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2957-2965 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Komp Lindgren, P., Hughes, D., Cars, O. (2006). Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57: 1116-1121 [Abstract] [Full Text]  
  • Drlica, K., Zhao, X., Blondeau, J. M., Hesje, C. (2006). Low Correlation between MIC and Mutant Prevention Concentration. Antimicrob. Agents Chemother. 50: 403-404 [Full Text]  
  • Campion, J. J., Chung, P., McNamara, P. J., Titlow, W. B., Evans, M. E. (2005). Pharmacodynamic Modeling of the Evolution of Levofloxacin Resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 2189-2199 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»